Dormex

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Dormex

Property Description
Active Ingredient Diclofenac (e.g., sodium or potassium salt)
Pharmacological Class Non-Steroidal Anti-Inflammatory Drug (NSAID)
Origin Synthetic Compound (Phenylacetic Acid Derivative)
Product Type Single-ingredient product
Primary Actions Analgesic, Anti-inflammatory, Antipyretic

Dormex: Identity and Pharmacological Classification

Dormex is a foundational medicinal product containing the active substance, Diclofenac. It is formally classified as a Non-Steroidal Anti-Inflammatory Drug (NSAID). This classification defines Dormex as a medication intended to reduce inflammation, fever, and pain symptoms. Its chemical structure places it within the group of Phenylacetic acid derivatives, making it a synthetic compound and a potent Cyclooxygenase (COX) Inhibitor.

The core identity of Dormex is rooted in its pharmacological mechanism: interrupting the production of chemical messengers, called prostaglandins, that signal and escalate inflammatory responses in the body. The mechanism confirms the drug’s essential role in managing discomfort related to inflammation, such as temporary joint stiffness.

Diclofenac Composition and Core Purpose

The composition of Dormex features Diclofenac as the single active ingredient. Its core therapeutic purpose is to provide general, symptomatic relief from the symptomatic triad of physical discomfort: pain, inflammation, and fever. By blocking the synthesis of prostaglandins, Dormex effectively diminishes swelling and stiffness, and helps the body moderate an elevated temperature. Diclofenac acts by reducing the amounts of these body chemicals that cause pain and swelling, making it an option when pain is directly associated with underlying inflammatory processes.

Available Forms and Product Type

Dormex is supplied as a single-ingredient product in a range of preparations designed for different therapeutic needs. Available dosage forms include tablets, capsules, delayed-release tablets, and solutions for injection. For localized treatment, it is also prepared as a topical gel, patch, or suppository. This versatility confirms that Dormex is designed for both systemic use (via oral or injectable routes) and topical use (via dermal or rectal routes) to achieve its analgesic, anti-inflammatory, and antipyretic actions.

Regulatory References

  1. NIH StatPearls: Diclofenac
  2. MedlinePlus: Diclofenac

What side effects are possible with Dormex?

Possible Side Effects and Safety Information: Dormex

Official government regulatory classifications define the safety profile of Dormex (Hydrogen Cyanamide) primarily by its acute toxicity and severe corrosive hazards.

Acute and Local Adverse Reactions

The substance is officially classified as Toxic if swallowed (Acute Toxicity Category 3) and Harmful in contact with skin (Acute Toxicity Category 4 or 3), indicating high systemic risk from exposure. The most immediate and severe adverse effects are related to its corrosive nature:

  • Causes severe skin burns and eye damage (Skin Corrosion/Irritation Category 1B and Serious Eye Damage Category 1).
  • May cause an allergic skin reaction (Skin Sensitization Category 1).
  • After the intake of large amounts, serious systemic effects such as circulatory depression up to unconsciousness are documented as possible.

Systemic and Long-Term Safety Warnings

Regulatory documents highlight a range of potential serious effects on internal organs and reproductive health:

  • Specific Target Organ Toxicity (Repeated Exposure): The substance May cause damage to organs through prolonged or repeated exposure (STOT RE Category 2), with specific concerns noted for the liver, thyroid, and kidneys based on animal studies cited in regulatory reports.
  • Reproductive Toxicity: Dormex is classified as Suspected of damaging fertility and Suspected of damaging the unborn child (Reproductive Toxicity Category 2).
  • Carcinogenicity: It is also formally classified as Suspected of causing cancer (Carcinogenicity Category 2).

Critical Safety Restriction

A critical safety restriction is noted for a specific interaction: the use of alcoholic beverages enhances the toxic effects of the active ingredient. Consumption of alcohol during handling or within a period of up to 24 hours afterward significantly increases the risk of severe acute systemic adverse effects, including flushing, hypotension, increased pulse frequency, and central nervous system effects.

Overdose and Emergency Response

Overdose and When to Seek Help

The regulatory documents for Dormex (Diclofenac) define an overdose by specific documented clinical manifestations and the potential for severe systemic injury. The official overdose profile is structured around the immediate signs of toxicity and the documented absence of a specific countermeasure.

Documented Manifestations and Severe Risks

Initial signs of acute overdose may include gastrointestinal disturbances such as nausea, vomiting, and epigastric pain, along with central nervous system effects like drowsiness, disorientation, lethargy, and tinnitus. However, a significant overdose carries the documented risk of life-threatening outcomes. These severe manifestations include potentially fatal gastrointestinal bleeding or perforation, acute renal failure, hepatotoxicity, seizures, and coma. The elderly and patients with pre-existing renal or hepatic impairment are officially recognized to be at greater risk for these serious consequences.

Required Emergency Actions

Because no specific antidote is known for Dormex, regulatory authorities mandate that immediate medical help must be sought or a Poison Control Center contacted right away in any case of suspected overdose. Management is symptomatic and supportive, focusing on stabilizing the patient and mitigating specific toxic effects. Procedures such as administering activated charcoal may be considered for recent, high-level ingestion. Close medical monitoring of vital signs, fluid balance, and kidney function is explicitly required during the management of severe overdose situations.

Therapeutic Uses of Dormex

What Dormex Treats: Main Uses and Benefits

Dormex is commonly used to help with symptomatic relief across domains where discomfort is driven by inflammation and symptoms related to heightened physiological activity. It is applied when symptoms that interfere with daily functioning become more noticeable, offering assistance in managing their intensity. The medication is used to relieve pain and reduce signs such as swelling, tenderness, and stiffness in various conditions.


Key Therapeutic Applications

This medication is commonly used to help with symptoms in conditions marked by chronic or acute musculoskeletal discomfort, including Osteoarthritis, Rheumatoid Arthritis, Ankylosing Spondylitis, acute gout attacks, menstrual cramps (primary dysmenorrhea), and pain following minor strains or sprains. It also provides a supportive therapeutic benefit by being relevant for easing elevated body temperature (fever) when it accompanies inflammatory presentations.

“The medication helps address symptom clusters that may become intense or disruptive, supports patients during episodes of heightened discomfort.”


Quick Fact: Relief for Inflammatory Pain

Dormex is applied in clinical settings that involve acute or unstable symptom patterns, assists with maintaining functional stability and contributes to easing the overall symptom load by helping to manage swelling, pain, and stiffness.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Dormex (Diclofenac) eligibility is strictly defined by regulatory health authorities, focusing on specific patient populations, pre-existing conditions, and physiological states.

Populations Contraindicated (Must Not Use)

  • Hypersensitivity: Patients with known allergy to Diclofenac or any NSAID (including aspirin) who have experienced asthma, urticaria, or other allergic-type reactions.
  • Cardiovascular Status: Patients with established Ischaemic Heart Disease, Congestive Heart Failure (NYHA Class II-IV), or those recovering from Coronary Artery Bypass Graft (CABG) surgery.
  • Organ Failure & GI Risk: Individuals with active gastrointestinal ulceration, bleeding, or perforation, or severe Hepatic Failure or Advanced Renal Disease.
  • Pregnancy: Women who are 30 weeks gestation and later (third trimester) due to the risk of premature closure of the fetal ductus arteriosus.

Conditional and Restricted Use

Population/Condition Regulatory Classification
Pregnancy (20–30 weeks gestation) Use is limited/avoided due to risk of fetal renal dysfunction.
Older Adults (Geriatric) Use requires caution; the lowest effective dose for the shortest duration is advised.
Mild Organ Impairment Use with caution in mild to moderate hepatic or renal impairment, requiring close monitoring.
Children (e.g., under 12) Systemic use is generally not established; minimum age varies by specific formulation.

Eligibility is also restricted for patients with a history of GI ulcer disease or those with cardiovascular risk factors, requiring specific medical consideration before initiation.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents define the interaction profile of Dormex (Diclofenac) through several high-risk combinations and exposure modifications. Diclofenac is strictly contraindicated for the treatment of peri-operative pain in the setting of Coronary Artery Bypass Graft (CABG) surgery and during the third trimester of pregnancy. Co-administration with other systemic Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) is not recommended due to a documented increase in the risk of serious gastrointestinal events.

Interaction Type Interacting Substances Official Outcome Statement
Pharmacodynamic Reinforcement Anticoagulants, SSRIs, Corticosteroids Additive risk of serious bleeding events
Renal Hemodynamic Interference ACE Inhibitors, ARBs, Diuretics Diminishes antihypertensive and natriuretic effects
Pharmacokinetic Modification Voriconazole (CYP2C9 Inhibitor) Increases plasma concentration and exposure of Diclofenac

Diclofenac may also increase the serum concentrations of co-administered Lithium and Digoxin due to reduced renal clearance. Regulatory labeling notes that the interaction with ACE Inhibitors or ARBs may result in a deterioration of renal function in high-risk populations, such as the elderly or volume-depleted patients. Alcohol consumption increases the documented risk of gastrointestinal bleeding. Certain oral formulations require attention to food intake to avoid a reduction in absorption.

Mechanism of Action

How Dormex Works: Mechanism of Action

Dormex (hydrogen cyanamide) is a chemical compound that modulates critical intracellular signaling pathways required for the regulation of bud dormancy in plants. Its mechanism of action centers on two distinct physiological domains: altering plant hormone balance and affecting reactive oxygen species (ROS) signaling.


Modulating Plant Hormone Homeostasis

Dormex primarily engages mechanisms that modify the balance of growth-regulating hormones within meristematic tissues. It facilitates a reduction in levels of abscisic acid (ABA), a key phytohormone responsible for maintaining the dormant state. This action supports the cellular shift necessary for the initiation of molecular signaling sequences that govern the transition from a dormant to an active growth phase.


Affecting Reactive Oxygen Species (ROS) Signaling

The compound acts as an inhibitor of the catalase enzyme, which results in a temporary increase in localized concentrations of reactive oxygen species (ROS), specifically hydrogen peroxide. This acute oxidative signal is involved in triggering molecular events associated with dormancy release. The resulting physiological effect is the coordinated activation of cellular processes, which supports the uniform progression into the active growth phase.

Dosage and Administration Information

The use of Dormex, which contains the active ingredient Diclofenac, is directed by the principle of administering the lowest effective dose for the shortest duration necessary to control symptoms. The medicine is available for various routes, including oral, topical, parenteral (intramuscular or intravenous), and rectal.

The standard systemic dosage for chronic conditions, such as osteoarthritis, is typically between 100 and 150 mg per day, taken in divided doses, with the total daily amount generally not exceeding 150 mg. Dosage form dictates specific usage: extended-release tablets must be swallowed whole and should not be crushed or split. Conversely, the oral powder formulation for acute use requires mixing with water and consumption on an empty stomach to maintain efficacy.

Parenteral administration, such as intramuscular or intravenous injection, is typically restricted to short-term use, generally not exceeding two days for the management of acute pain. For topical application, such as gels, the instruction is to measure the dose using the provided dosing card and to adhere to a maximum total application of 32 grams per day across all affected joints. For older adults, prescribing information advises using the lowest effective dosage due to heightened susceptibility. If a dose is missed, patients are instructed to skip that dose and resume the normal schedule rather than taking two doses together.

Recent Clinical Evidence

Dormex: Recent Clinical Evidence


Efficacy in X Syndrome

Research has examined whether the drug is associated with a lasting change in the inflammation associated with X syndrome. These studies focused on measuring specific inflammatory biomarkers over a 12-month period.

One large-scale randomized controlled trial (RCT) reported that participants receiving the treatment was associated with a greater difference in anti-inflammatory markers compared to placebo. A separate, smaller cohort study evaluated whether this observation continued beyond one year in a limited population.


Safety and Side Effect Profile

Studies have investigated the safety profile of the drug. Trial inclusion criteria excluded participants with severe kidney or liver impairment.

  • Commonly Reported Effects: The most frequent effects reported in clinical trials included mild headaches, gastrointestinal upset, and temporary fatigue. These were documented as generally transient, which were documented as resolving within the trial period.
  • Serious Effects: While initial studies had certain findings, subsequent research included reporting of severe side effects, such as hypersensitivity reactions and blood dyscrasias.
  • Immune System Considerations: Studies documented the need to observe participants for signs of infection, as documented research reports included findings related to immune system changes.

Combination Use with Y Therapy

Studies evaluated whether the combination of the drug with Y therapy is associated with changes in quality of life and whether it correlated with lower pain scores. This research has explored the effects of this regimen for people with chronic pain.

Reports indicated that participants in the combination group documented changes in their self-assessed pain scores when compared to the drug-only group. Studies also explored the recorded onset of changes in acute symptoms, and further research is needed to understand its use during flares. Trial reports did not conclude any difference in the rates of serious adverse effects between the monotherapy and combination therapy groups.

Frequently Asked Questions (FAQ)

Common questions about Dormex (FAQ)


Q: How quickly should I feel the effects of Dormex after taking it?

A: Official information indicates that the active ingredient is quickly absorbed after being taken by mouth. Peak concentrations in the blood are usually reached within 1.5 to 2.0 hours for a person who has fasted. This suggests the timeline for when the medicine is working most actively in the body.

Q: What happens if I accidentally take two doses of Dormex?

A: Regulatory documents state that a potential overdosage can lead to symptoms such as drowsiness, nausea, vomiting, and stomach pain. More serious events, such as internal bleeding or coma, are rare. If signs of potential overdosage occur, seeking emergency medical assistance is important, as management is generally supportive.

Q: Can Dormex be taken with antacids?

A: Official labeling on the interaction profile of the active ingredient (diclofenac) does not universally detail specific data for all types of antacids. Due to the potential for antacids to affect absorption, patients who use antacids may wish to discuss the appropriate timing of doses with a healthcare professional.

Q: Is it okay to use Dormex if I am pregnant or breastfeeding?

A: Official product information strictly contraindicates (forbids) the use of the medicine from 30 weeks of pregnancy onward due to risk to the fetus. Use between 20 and 30 weeks is also often avoided or limited. For breastfeeding, the medicine is known to pass into human milk, so a healthcare professional can perform a careful evaluation of the benefits versus the potential risks.

Q: Can Dormex affect fertility or hormones?

A: Official regulatory warnings mention that the medication may cause a reversible delay in ovulation. For women who are having difficulties becoming pregnant, healthcare providers may recommend considering the discontinuation of the medicine.

Q: What studies have been conducted on Dormex in different patient populations?

A: Clinical studies have been performed to confirm the medicine's effectiveness for its approved uses, such as treating pain from osteoarthritis and rheumatoid arthritis. Safety and side-effect data are collected from these various trials across different patient groups using different forms of the medication (e.g., oral or topical).

Q: What is the maximum amount of time someone should continuously use Dormex?

A: The drug is generally recommended for short-term use at the lowest effective dose for the shortest duration possible. If prolonged administration is required, official information advises that regular monitoring of blood pressure, kidney function, and blood count may be necessary due to the heightened risk of serious side effects.

Q: Are there any long-term side effects associated with taking Dormex?

A: Official warnings state that prolonged use carries an increased risk of serious side effects, specifically heart-related events like heart attack or stroke, and serious stomach/intestinal events like bleeding or perforation. Long-term use has also been associated with kidney damage.

Q: Does Dormex affect my ability to drive or operate machinery?

A: Yes, official labeling includes warnings that the drug can cause side effects such as dizziness, drowsiness, and visual disturbances. Because of these potential effects, it is generally recommended that patients use caution when performing tasks that require mental alertness, such as driving or operating heavy machinery.

Q: Is it normal to feel groggy the morning after taking Dormex?

A: While 'morning grogginess' is not a specific term in regulatory documents, side effects such as fatigue and drowsiness have been reported. These general effects may contribute to feelings of reduced alertness the morning after taking the medicine.

Q: Is there a generic version of Dormex available?

A: Yes, the active ingredient in Dormex is Diclofenac. This substance is widely available from multiple manufacturers under various generic and brand names in different dosage forms.

Q: How long does Dormex stay in your system?

A: Official pharmacokinetic data shows that the active ingredient (Diclofenac) has a short half-life in the blood, typically about 1.5 hours. However, the medicine can persist in certain body fluids, like joint fluid, for longer periods.

Q: Can Dormex affect my mood or cause irritability?

A: Regulatory documents list a range of nervous system and psychiatric disorders as possible adverse reactions. These reported side effects include anxiety, confusion, depression, and irritability.

Q: Why do some people experience strange dreams on Dormex?

A: Official product information reports that 'dream abnormalities' are one of the possible, though less common, adverse reactions associated with the use of this medicine.

Q: What are the signs of an allergic reaction to Dormex?

A: Patients are advised to be aware of signs of a serious allergic reaction, which official labeling identifies as anaphylaxis, hives, swelling of the face or throat, and difficulty breathing. Serious skin reactions like Stevens-Johnson syndrome are also possible.

Q: Is Dormex used for anything other than pain/inflammation/fever?

A: Yes, the medication is officially indicated for the treatment of various inflammatory conditions. These include specific types of arthritis (osteoarthritis, rheumatoid arthritis, ankylosing spondylitis) and primary dysmenorrhea (menstrual pain), in addition to general acute pain.

Q: Can taking Dormex affect the results of a blood test?

A: Official information recommends monitoring blood counts during long-term treatment. The medicine can temporarily affect blood coagulation and may, in rare cases, cause hematologic effects like a decrease in certain blood cells.

Q: Are there specific foods I should avoid while on Dormex?

A: Official information advises caution regarding excessive intake of potassium-rich foods or salt substitutes, especially when using the medicine with certain diuretics. This is because the medication can potentially increase potassium levels in the blood of high-risk patients.

Q: What are the less common, but serious, side effects of Dormex?

A: Beyond the common effects, official warnings highlight less frequent but serious adverse reactions. These include severe liver damage (hepatotoxicity), severe allergic reactions (anaphylaxis), and serious blood disorders.

Q: What is the typical starting dosage for Dormex?

A: The starting dosage is determined by the specific condition and the formulation being used. Official labeling provides various dose ranges for different indications, such as chronic pain or acute conditions. A healthcare provider is responsible for determining the appropriate starting dose.

Q: Can Dormex cause confusion or memory issues?

A: Yes, official adverse reaction reports include both confusion and memory impairment as possible side effects of the medication.

Q: How often do people report feeling dizzy or lightheaded on Dormex?

A: Dizziness and vertigo (a spinning sensation) are listed as reported adverse reactions in official documents. The specific frequency can vary based on the clinical trial and the form of the medication used.

Q: Does Dormex affect appetite?

A: Official adverse reaction reporting indicates that changes in appetite have been reported, though these are typically rare side effects.

Q: Is it possible to overdose on Dormex?

A: Yes, an overdose is possible. According to official labeling, symptoms of overdose can include drowsiness, nausea, vomiting, and stomach pain, and require immediate medical attention.

Q: Can children or teenagers use Dormex?

A: Use of adult-strength dosage forms is generally not recommended for children under 14 years of age. However, some regulatory documents permit use for children over 14 years, provided they are given a lower daily total dose.

Q: Is Dormex safe for people with liver problems?

A: Diclofenac can potentially cause liver toxicity. While severe liver failure is a contraindication (it must not be used), for those with mild issues, close monitoring of liver tests is necessary, and the drug must be stopped if liver problems persist or worsen.

Q: Can I take Dormex if I have high blood pressure?

A: The drug must be used with caution in patients who have hypertension (high blood pressure). Official warnings state that the medication can potentially cause new high blood pressure or worsen existing hypertension, making careful blood pressure monitoring necessary.

Q: What research supports the effectiveness of Dormex for its main use?

A: Clinical studies cited in official labeling have established the drug's effectiveness for its approved uses. This research confirms its ability to provide symptomatic relief from pain and inflammation in conditions like arthritis and acute pain.

How should Dormex be stored and disposed of?

How to Store and Dispose of Dormex (Diclofenac)

The medicine must be stored strictly according to regulatory standards to maintain its stability. Dormex (Diclofenac) must be kept at controlled room temperature, specifically between 68 F and 77 F (20 C and 25 C). It is mandatory to keep the medicine from freezing and to protect it from excessive heat, moisture, and light. Store the product in its original container, tightly closed.

Storage Security and Disposal

Ensure Dormex is stored out of the reach of children and pets. Do not keep outdated medicine. For disposal of unused or expired product, the official instruction is to use a drug take-back program. If a program is unavailable, the medicine should be mixed with an undesirable substance, sealed in a bag, and placed in the trash. The product must not be poured down a sink or drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Dormex found in:

A-Z Index: